Dr. Reddy's Laboratories, Alvotech enter into license agreement

05 Jun 2025 Evaluate

Dr. Reddy's Laboratories and Alvotech have entered into a collaboration and license agreement to codevelop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types.

In 2024, worldwide sales of Keytruda were $29.5 billion. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1268.40 -0.65 (-0.05%)
29-Dec-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.70
Dr. Reddys Lab 1268.40
Cipla 1495.00
Zydus Lifesciences 906.25
Lupin 2082.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×